Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

TRENDING
Mobile Game Revenue Steadily Recovering, Report Says
Henlius Biotech Raises $410 Million in Hong Kong IPO
Chinese Smartphone-Maker, Big in Africa, Prices IPO Far Above Apple
LATEST
China Expected to Have First Self-Designed DRAM Chip by Year End
Chinese Gaming Giant NetEase to Raise More Pigs
AB InBev Asian IPO Price Polling Below Midpoint of Range, Again
iPhone 11 Released in China to Mixed Reception From Shoppers
Pony Ma Steps Down as Tencent Credit’s Legal Representative
Local Emissions-Cutting Projects Could Help China Surpass International Commitments: Report
Short-Term Reference Rate for Loan Pricing Edges Down
Tencent Offers Open-Source System for IoT Innovation
Chinese Smartphone-Maker, Big in Africa, Prices IPO Far Above Apple
Dajia Insurance Launches Online Shop
World’s Highest Grid Project Takes Shape on ‘Roof of the World’
Battery Giant CATL in $1.4 Billion Fund-Raising Plan
Alibaba Recruits Big-Hitters for AI Research Labs
Zhejiang Regulators May Struggle to Implement Consumer Loan Rules
Is This Chinese Local Government Using a Journalist’s Trial to Quash Dissent?
ABB Bulks Up With Huawei on Industrial Cloud
China Biologic Receives $4.6 Billion Buyout Offer
Henlius Biotech Raises $410 Million in Hong Kong IPO
Mobile Game Revenue Steadily Recovering, Report Says
China’s Cybersecurity Industry Expected to Grow 23% to $8.9 Billion
Market Rattled by Kangmei’s $4.4 Billion Accounting Error

By Wang Juanjuan and Han Wei / May 01, 2019 12:37 AM / Finance

Photo: VCG

Photo: VCG

Shares and bonds of one of China’s largest listed drugmakers tumbled Tuesday after the company restated 29.9 billion yuan ($4.4 billion) of 2017 results, fueling suspicions of fraud.

Shanghai-listed Kangmei Pharmaceutical Co. Ltd., a producer of traditional Chinese medicines, said in a filing that there were multiple “accounting errors” in its 2017 results, leading to 29.9 billion yuan overstatement of the company’s cash holding. Late last year, Kangmei said it was investigated by securities regulators for suspected violations of information disclosure rules.

Kangmei’s stock, a component of MSCI Inc.’s global indexes, slumped by the 10% daily limit. The company’s bonds fell by 20%.

Several audit professionals said they were concerned that there may be problems in Kangmei’s financials beyond accounting errors, given the vague language and lack of logic in its correction statement. They said they suspected the company may have intentionally inflated its cash holding and inventories to boost profit.

Guangfa Securities and GP Certified Public Accountants Co. Ltd. have served in Kangmei’s financial and accounting operations.

Kangmei was involved in several bribery cases involving government officials. According to court documents released last June, the company bribed Cai Ming, former director of the drug safety supervision department at the Guangdong Province Food and Drug Administration, to the tune of 300,000 yuan from 2014 to 2015.

In February, the company was rattled by default risks on $300 million of bonds. The crisis was eased later after the Guangdong provincial government stepped in.

This story has been updated to correct the year of Kangmei’s financial report that contained errors. The report was for the year 2017, and it contained multiple errors.

Related: Pharmaceutical Firm Avoids Default as Guangdong Pressures Customers

Share this article
Open WeChat and scan the QR code